Sofinnova closes €650m healthcare fund for early-stage ventures

Sofinnova Partners has closed its latest Sofinnova Capital XI fund, aimed at supporting early-stage healthcare companies in the US and Europe, at €650m ($750m) above its initial target. The fund will focus on medical technology and biopharmaceutical companies that seek to meet pressing unmet clinical needs, leveraging Sofinnova’s multi-strategy platform and investment team. It will leverage the experience of partners Maina Bhaman, Anta Gkelou, Karl Naegler, Antoine Papiernik, Henrijette Richter and Grazi ...